We bring expertise from chemistry, materials science and quantitative multiscale imaging to prepare probes to study complex biological processes at a molecular level and apply in preclinical and clinical models. Our interest lies in emerging imaging modalities, e.g., fluorescence (second biological window/NIR-II), photoacoustic, hyperspectral and photon counting CT.
Image Guided Therapeutics
Our lab is interested in exploring various pathways for cancer regression including novel genetic target, metabolic therapy, inhibiting signaling pathways by targeting stem cell marker, nuclear receptor, etc. This process either involves repurposing of existing clinically approved therapeutics or structure-based drug discovery to develop activatable nanotherapy. Other areas of interests are oxygen therapeutic and blood disease.
We are interested in developing point-of-care (POC) biosensors for objective assessment of disease by detection of novel biomarkers in human tear fluid and biodegradable electronics. For this part of the work, our goal is to use biological samples identify novel biomarkers through proteomic analysis and develop biosensors for infectious diseases, objective assessment for eye injuries or other systemic diseases. Other enquiries include the development of POC sensor for traumatic brain injury and neurological disorders.